Cancer Research Cell Death Mechanisms and Cancer Therapy Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cai, W.
Right arrow Articles by Chen, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cai, W.
Right arrow Articles by Chen, X.
[Cancer Research 66, 9673-9681, October 1, 2006]
© 2006 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin {alpha}vß3

Weibo Cai1, Yun Wu1, Kai Chen1, Qizhen Cao1, David A. Tice2 and Xiaoyuan Chen1

1 The Molecular Imaging Program at Stanford, Department of Radiology and Bio-X Program, Stanford University School of Medicine, Stanford, California and 2 MedImmune, Inc., Gaithersburg, Maryland

Requests for reprints: Xiaoyuan Chen, The Molecular Imaging Program at Stanford, Department of Radiology and Bio-X Program, Stanford University School of Medicine, 1201 Welch Road, P095, Stanford, CA 94305-5484. Phone: 650-725-0950; Fax: 650-736-7925; E-mail: shawchen{at}stanford.edu.

AbegrinTM (MEDI-522 or VitaxinTM), a humanized monoclonal antibody against human integrin {alpha}vß3, is in clinical trials for cancer therapy. In vivo imaging using AbegrinTM-based probes is needed for better treatment monitoring and dose optimization. Here, we conjugated AbegrinTM with macrocyclic chelating agent 1,4,7,10-tetra-azacylododecane N,N',N'',N'''-tetraacetic (DOTA) at five different DOTA/AbegrinTM ratios. The conjugates were labeled with 64Cu (half-life = 12.7 hours) and tested in three human (U87MG, MDA-MB-435, and PC-3) and one mouse (GL-26) tumor models. The in vitro and in vivo effects of these 64Cu-DOTA-AbegrinTM conjugates were evaluated. The number of DOTA per AbegrinTM varied from 1.65 ± 0.32 to 38.53 ± 5.71 and the radiolabeling yield varied from 5.20 ± 3.16% to 88.12 ± 6.98% (based on 2 mCi 64Cu per 50 µg DOTA-AbegrinTM conjugate). No significant difference in radioimmunoreactivity was found among these conjugates (between 59.78 ± 1.33 % and 71.13 ± 2.58 %). Micro-positron emission tomography studies revealed that 64Cu-DOTA-AbegrinTM (1,000:1) had the highest tumor activity accumulation (49.41 ± 4.54% injected dose/g at 71-hour postinjection for U87MG tumor). The receptor specificity of 64Cu-DOTA-Abegrin was confirmed by effective blocking of MDA-MB-435 tumor uptake with coadministration of nonradioactive Abegrin. 64Cu-DOTA-IgG exhibited background level tumor uptake at all time points examined. Integrin {alpha}vß3-specific tumor imaging using 64Cu-DOTA-AbegrinTM may be translated into the clinic to characterize the pharmacokinetics, tumor targeting efficacy, dose optimization, and dose interval of AbegrinTM and/or Abegrin conjugates. Chemotherapeutics or radiotherapeutics using AbegrinTM as the delivering vehicle may also be effective in treating integrin {alpha}vß3-positive tumors. (Cancer Res 2006; 66(19): 9673-81)




This article has been cited by other articles:


Home page
 RadiologyHome page
F. Kiessling, J. Huppert, C. Zhang, J. Jayapaul, S. Zwick, E. C. Woenne, M. M. Mueller, H. Zentgraf, M. Eisenhut, Y. Addadi, et al.
RGD-labeled USPIO Inhibits Adhesion and Endocytotic Activity of {alpha}v{beta}3-Integrin-expressing Glioma Cells and Only Accumulates in the Vascular Tumor Compartment
Radiology, November 1, 2009; 253(2): 462 - 469.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Zannetti, S. Del Vecchio, F. Iommelli, A. Del Gatto, S. De Luca, L. Zaccaro, A. Papaccioli, J. Sommella, M. Panico, A. Speranza, et al.
Imaging of {alpha}v{beta}3 Expression by a Bifunctional Chimeric RGD Peptide not Cross-Reacting with {alpha}v{beta}5
Clin. Cancer Res., August 15, 2009; 15(16): 5224 - 5233.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Niu, Z. Li, J. Xie, Q.-T. Le, and X. Chen
PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models
J. Nucl. Med., July 1, 2009; 50(7): 1116 - 1123.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Z. Liu, Z.-B. Li, Q. Cao, S. Liu, F. Wang, and X. Chen
Small-Animal PET of Tumors with 64Cu-Labeled RGD-Bombesin Heterodimer
J. Nucl. Med., July 1, 2009; 50(7): 1168 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
R. OHASHI, K. TAJIMA, F. TAKAHASHI, R. CUI, T. GU, K. SHIMIZU, K. NISHIO, K. FUKUOKA, T. NAKANO, and K. TAKAHASHI
Osteopontin Modulates Malignant Pleural Mesothelioma Cell Functions In Vitro
Anticancer Res, June 1, 2009; 29(6): 2205 - 2214.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. M. Wu
Antibodies and Antimatter: The Resurgence of Immuno-PET
J. Nucl. Med., January 1, 2009; 50(1): 2 - 5.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
W. Cai, R. Guzman, A. R. Hsu, H. Wang, K. Chen, G. Sun, A. Gera, R. Choi, T. Bliss, L. He, et al.
Positron Emission Tomography Imaging of Poststroke Angiogenesis
Stroke, January 1, 2009; 40(1): 270 - 277.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
A. H. Schmieder, S. D. Caruthers, H. Zhang, T. A. Williams, J. D. Robertson, S. A. Wickline, and G. M. Lanza
Three-dimensional MR mapping of angiogenesis with {alpha}5{beta}1({alpha}{nu}{beta}3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model
FASEB J, December 1, 2008; 22(12): 4179 - 4189.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Veeravagu, Z. Liu, G. Niu, K. Chen, B. Jia, W. Cai, C. Jin, A. R. Hsu, A. J. Connolly, V. Tse, et al.
Integrin {alpha}v{beta}3-Targeted Radioimmunotherapy of Glioblastoma Multiforme
Clin. Cancer Res., November 15, 2008; 14(22): 7330 - 7339.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Cao, W. Cai, G. Niu, L. He, and X. Chen
Multimodality Imaging of IL-18-Binding Protein-Fc Therapy of Experimental Lung Metastasis
Clin. Cancer Res., October 1, 2008; 14(19): 6137 - 6145.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
P. M. Winter, A. H. Schmieder, S. D. Caruthers, J. L. Keene, H. Zhang, S. A. Wickline, and G. M. Lanza
Minute dosages of {alpha}{nu}{beta}3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits
FASEB J, August 1, 2008; 22(8): 2758 - 2767.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
P. T. Winnard Jr., A. P. Pathak, S. Dhara, S. Y. Cho, V. Raman, and M. G. Pomper
Molecular Imaging of Metastatic Potential
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 96S - 112S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Cai and X. Chen
Multimodality Molecular Imaging of Tumor Angiogenesis
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 113S - 128S.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Wang, K. Chen, W. Cai, Z. Li, L. He, A. Kashefi, and X. Chen
Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein
Mol. Cancer Ther., May 1, 2008; 7(5): 1044 - 1053.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Z.-B. Li, Z. Wu, K. Chen, E. K. Ryu, and X. Chen
18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging
J. Nucl. Med., March 1, 2008; 49(3): 453 - 461.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. A.M.S. van Dongen, G. W.M. Visser, M. N. Lub-de Hooge, E. G. de Vries, and L. R. Perk
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications
Oncologist, December 1, 2007; 12(12): 1379 - 1389.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Cai, K. Chen, Z.-B. Li, S. S. Gambhir, and X. Chen
Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature
J. Nucl. Med., November 1, 2007; 48(11): 1862 - 1870.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. D. Voss, S. V. Smith, N. DiBartolo, L. J. McIntosh, E. M. Cyr, A. A. Bonab, J. L. J. Dearling, E. A. Carter, A. J. Fischman, S. T. Treves, et al.
Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates
PNAS, October 30, 2007; 104(44): 17489 - 17493.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. R. Hsu, W. Cai, A. Veeravagu, K. A. Mohamedali, K. Chen, S. Kim, H. Vogel, L. C. Hou, V. Tse, M. G. Rosenblum, et al.
Multimodality Molecular Imaging of Glioblastoma Growth Inhibition with Vasculature-Targeting Fusion Toxin VEGF121/rGel
J. Nucl. Med., March 1, 2007; 48(3): 445 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Mulgrew, K. Kinneer, X.-T. Yao, B. K. Ward, M. M. Damschroder, B. Walsh, S.-Y. Mao, C. Gao, P. A. Kiener, S. Coats, et al.
Direct targeting of {alpha}v{beta}3 integrin on tumor cells with a monoclonal antibody, AbegrinTM
Mol. Cancer Ther., December 1, 2006; 5(12): 3122 - 3129.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.